{
  "denotations": [
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 50,
        "end": 59
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 64,
        "end": 73
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 91,
        "end": 118
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 121,
        "end": 127
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 135,
        "end": 167
      }
    },
    {
      "id": "T8",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 170,
        "end": 174
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 14,
        "end": 40
      }
    },
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 43,
        "end": 47
      }
    },
    {
      "id": "T10",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 14,
        "end": 29
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "20512075_2",
  "text": "PURPOSE : The tyrosine kinase inhibitors ( TKIs ) gefitinib and erlotinib are effective in non-small cell lung cancers ( NSCLCs ) with epidermal growth factor receptor ( EGFR ) gene mutations ."
}
